Impact of CYP3A4 and ABCB1 genetic variants on tacrolimus dosing in Greek kidney transplant recipients
It remains uncertain whether these genetic variants influence the assessment of the appropriate tacrolimus dosing 1 year after transplantation in Greek kidney transplant recipients.
Authors
- Stavroula Siamoglou
- George P. Patrinos (ORCID: https://orcid.org/0000-0002-0519-7776)
- Konstantinos Lazaros (ORCID: https://orcid.org/0000-0002-9527-3946)
- Kyriaki Kydonopoulou
- Alexandra Gerou
- Anna Tsironi
- Marios Papasotiriou (ORCID: https://orcid.org/0000-0001-9375-989X)
- Effrosyni Mendrinou
- Aristidis G. Vrahatis (ORCID: https://orcid.org/0000-0003-1892-0000)
- Bassam R. Ali (ORCID: https://orcid.org/0000-0003-1306-6618)
- Spyridon Gerou
- Anne John
Institutions
- University of Patras (GR)
- Ionian University (GR)
- United Arab Emirates University (AE)
- National Centre of Scientific Research "Demokritos" (GR)
- General University Hospital of Patras (GR)
- Erasmus MC (NL)
- Alexander Fleming Biomedical Sciences Research Center (GR)
- Zayed University (AE)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-03-19
- DOI
- https://doi.org/10.3389/fphar.2025.1538432
- Citations
- 2
- Primary Topic
- Renal Transplantation Outcomes and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 3.97
Funders
- European Commission